The Sai Parenteral IPO is set to hit the market next week, and there’s already quiet buzz building around it. For investors tracking fresh listings, this IPO brings a mix of steady pharma business, moderate growth numbers, and a clearly defined use of funds.
Let’s break it down—simply, clearly, and without the noise.
Sai Parenteral IPO Dates & Market Performance Snapshot
The Sai Parenteral IPO will open for subscription on March 24 and close on March 27.
- IPO Type: Book-built issue
- Total Issue Size: ₹408.79 crore
- Listing: BSE and NSE
This puts Sai Parenteral among the mid-sized pharma IPOs entering the market this season.
Main News: Sai Parenteral IPO Structure & Fundraising Plan
At its core, the Sai Parenteral IPO is structured to balance fresh capital inflow with partial stake dilution.
- Fresh Issue: ₹285 crore
- Offer for Sale (OFS): ₹123.79 crore
- Total Shares (Fresh Issue): 0.73 crore shares
- Shares in OFS: 0.32 crore shares
The fresh issue is where the company raises new capital, while the OFS allows existing shareholders to reduce their holdings.
Where Will the Money Go?
The company has clearly outlined how it plans to use the fresh funds:
- Expansion and upgrade of manufacturing facilities
- Setting up a new R&D centre
- Repayment of existing debt
- Working capital requirements
- General corporate purposes
It’s a straightforward deployment plan, focused on scaling operations and strengthening the balance sheet.
Selling Shareholders in Sai Parenteral IPO
A part of the IPO includes stake sales by existing investors.
Key names participating in the OFS include:
- Vikasa India EIF I Fund
- Tilokchand Punamchand Ostwal
- Bhanwar Lal Chandak
- Devendra Chawla
- Sreelekha Ganta
- Ashish Maheshwari
- Vijay Gondi
- Padma Guntupalli
- Nilesh Pravinchandra Doshi
- Bhautik Mukund Shah
These investors are offloading a portion of their holdings through the IPO route.
Company Details: What Sai Parenteral Actually Does?
Sai Parenteral operates in the pharmaceutical formulations space. It’s not just a single-product company—it has a diversified setup.
Core Business Segments
- Branded generics
- CDMO (Contract Development and Manufacturing Organization)
Therapeutic Coverage
The company’s product portfolio spans multiple segments:
- Cardiovascular
- Anti-diabetic
- Neuropsychiatry
- Respiratory
- Antibiotics
- Vitamins, minerals, and supplements (VMS)
- Gastroenterology
- Analgesics
- Dermatology
Dosage Forms Offered
Sai Parenteral works across various formats:
- Tablets
- Injectables
- Capsules
- Liquid orals
- Ointments
This wide product mix gives it presence across multiple treatment categories.
Financial Overview of Sai Parenteral IPO
Let’s get straight to the numbers. No fluff.
Recent Financial Performance
For 6 months ended September 2025:
- Revenue: ₹86.9 crore
- Net Profit: ₹7.7 crore
For FY25:
- Revenue: ₹163.1 crore (up 6%)
- Net Profit: ₹14.4 crore (up 71.8%)
For FY24:
- Revenue: ₹153.8 crore
- Net Profit: ₹8.4 crore
What Stands Out?
- Revenue growth is steady, not aggressive
- Profit growth is sharper, indicating improved efficiency
Industry Context: Pharma Sector Growth
The company operates in a growing global pharmaceutical market.
- Market Size (2025): $1.8 trillion
- Projected Size (2033): $2.9 trillion
- Growth Rate: 5.9% CAGR
Growth is being supported by:
- Rising healthcare demand
- Innovation in treatments
- Expansion of affordable generics
Key Risk Factors to Watch
Every IPO comes with risks, and the Sai Parenteral IPO is no different.
High Dependence on Injectables
A large portion of revenue comes from injectables:
- FY25: 44.78%
- FY24: 47.64%
- FY23: 92.03%
This concentration means:
- Any drop in injectable demand can impact revenue
- Business performance is closely tied to one segment
Subsidiaries of Sai Parenteral
The company operates through a mix of domestic and international subsidiaries.
Indian Subsidiaries
- Revat Laboratories Private Limited
- SP Analytics Private Limited
Foreign Subsidiaries
- Sai Parenterals Pte. Limited
Step-down Subsidiaries
- Noumed Pharmaceuticals Pty Limited
- Noumed Pharmaceuticals Limited
This structure supports both domestic operations and international presence.
IPO Management Details
- Lead Manager: Arihant Capital Markets Ltd.
- Registrar: Bigshare Services
These entities are responsible for managing and processing the IPO.
Summary: Sai Parenteral IPO in a Nutshell
The Sai Parenteral IPO is a ₹408.79 crore issue combining fresh capital and stake sale.
Here’s the quick takeaway:
- Opens March 24, closes March 27
- Balanced structure: fresh issue + OFS
- Funds aimed at expansion, R&D, and debt repayment
- Stable revenue growth, strong profit growth
- Heavy reliance on injectables remains a key risk
- Operates in a growing global pharma market
It’s a simple story—steady business, clear plans, and a focused pharma play.
Source: Livemint
Easy & quick